
Refractory follicular B-cell non-Hodgkin's lymphoma Program in Pharmaceutical Benefits Scheme (PBS) 012-18051115

-   Background
-   Process
-   Resources

[Expand/Collapse all sections]Expand all

This document outlines details of the previous Pharmaceutical Benefits
Scheme (PBS) subsidised idelalisib for patients with Refractory
follicular B-cell non-Hodgkin's lymphoma (FBHL).

This program has been moved to the general schedule from 1 January 2022
and this page is for informational purposes only.

Refractory follicular B-cell non-Hodgkin’s lymphoma and listing dates

Refractory follicular B-cell non-Hodgkin’s lymphoma (FBHL) is a type of
blood cancer.

Listing dates are as follows:

-   idelalisib - 1 September 2017

See Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA)
for further information.

Enquiries

Transfer enquiries about prescription arrangements to the PBS authority
approvals line.

The Resources page contains links to contact details, the Pharmaceutical
Benefits Scheme (PBS) and Services Australia website.

Related links

Process telephone Authority approval application

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

                                   

-   Services Australia ABN 90 794 605 008 
